Stem Cell Authority Stock Fundamentals
| SCAL Stock | USD 0.0001 0.00 0.00% |
Fundamental analysis of Stem Cell allows traders to better anticipate movements in Stem Cell's stock price by examining its financial health and performance throughout various phases of its business cycle.
Stem |
Stem Cell Authority Company Return On Asset Analysis
Stem Cell's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Stem Cell Return On Asset | 0.49 |
Most of Stem Cell's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Stem Cell Authority is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Stem Cell Authority has a Return On Asset of 0.4909. This is 105.61% lower than that of the Healthcare sector and significantly higher than that of the Medical Care Facilities industry. The return on asset for all United States stocks is notably lower than that of the firm.
Stem Cell Authority Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Stem Cell's current stock value. Our valuation model uses many indicators to compare Stem Cell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Stem Cell competition to find correlations between indicators driving Stem Cell's intrinsic value. More Info.Stem Cell Authority is currently regarded as top stock in return on asset category among its peers. It also is currently regarded as top stock in profit margin category among its peers fabricating about 1.12 of Profit Margin per Return On Asset. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Stem Cell's earnings, one of the primary drivers of an investment's value.Stem Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Stem Cell's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Stem Cell could also be used in its relative valuation, which is a method of valuing Stem Cell by comparing valuation metrics of similar companies.Stem Cell is currently under evaluation in return on asset category among its peers.
Stem Fundamentals
| Return On Asset | 0.49 | |||
| Profit Margin | 0.55 % | |||
| Operating Margin | 0.55 % | |||
| Current Valuation | 9.15 M | |||
| Shares Outstanding | 348.71 M | |||
| Price To Earning | 2.00 X | |||
| Price To Sales | 1.05 X | |||
| Revenue | 3.33 M | |||
| Gross Profit | 2.27 M | |||
| Net Income | 1.83 M | |||
| Cash And Equivalents | 39.84 K | |||
| Total Debt | 675.1 K | |||
| Debt To Equity | 4.88 % | |||
| Current Ratio | 1.12 X | |||
| Earnings Per Share | 0.01 X | |||
| Beta | -71.45 | |||
| Market Capitalization | 2.34 M | |||
| Total Asset | 3.99 M | |||
| Z Score | 1.8 | |||
| Net Asset | 3.99 M |
About Stem Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Stem Cell Authority's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Stem Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Stem Cell Authority based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. The companys technology enables birthing professionals with a stem cell preservation program to serve their maternity patients in the United States. Stem Cell operates under Medical Care Facilities classification in the United States and is traded on OTC Exchange.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Stem Pink Sheet
Stem Cell financial ratios help investors to determine whether Stem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stem with respect to the benefits of owning Stem Cell security.